Recent studies have demonstrated that peroxisome proliferator-activated receptora (PPAR-a) agonists can protect the brain against excessive oxidative stress and inflammation in traumatic brain injury (TBI) and stroke through endogenous PPAR-a. However, it has not been investigated whether, and to what degree, cerebral expression of PPAR-a changes after TBI, especially in the human brain. In this study, 12 contused brain samples were obtained from 11 patients undergoing surgery for TBI 6 -98 h after trauma. PPAR-a binding activity was measured by electrophoretic mobility shift assay, and temporal and cellular expression of PPAR-a by immunohistochemistry. The results showed that a persistent upregulation of PPAR-a binding activity and protein expression occurred in injured cortex after TBI, which peaked 24 -72 h post-injury. Expression of PPARa was mainly located in glial and vascular endothelial cells with a little expression in the neurons. It is concluded that TBI could greatly upregulate the binding activity and protein expression of PPAR-a in injured human brain, which might be important in brain pathophysiology after TBI.
Introduction
Although traumatic brain injury (TBI) represents a significant public health problem worldwide, there are currently no treatments that improve clinical outcome. 1, 2 Recently, several reports from experimental studies have demonstrated that fenofibrate, a peroxisome proliferator-activated receptor α (PPAR-α) agonist, plays neuroprotective roles in TBI by counteracting the deleterious oxidative stress and inflammatory response following TBI. 3, 4 Fenofibrate, however, failed to protect the brain in PPAR-α knockout mice, which indicated that this PPAR-α agonist protects the brain through endogenous PPAR-α. 5 In addition, as reported by Genovese et al., 6 the absence of a functional PPAR-α gene resulted in significant augmentation of oedema, neutrophil infiltration, apoptosis and tumour necrosis factor α (TNF-α) immunoreactivity after spinal cord trauma. In drawing conclusions from all these previous studies, it appears that endogenous PPAR-α D Feng, Y Zhang, G Chen Cortical expression of PPAR-a after brain contusion transduces cytoprotective signals in the brain. Nevertheless, to our knowledge, the cerebral expression of PPAR-α during TBI has not been previously investigated, especially for TBI patients. We put forward the hypothesis that, as a neuroprotective agent, PPAR-α would be activated to modulate the signals of the nuclear factor-κB (NF-κB) pathway at an early stage after TBI. The aim of the present study was, therefore, to evaluate the binding activity and temporal and cellular expression pattern of PPAR-α following a lesion biopsy in human brain contusion.
Patients and methods

PATIENTS
This study was approved by the Southeast University's Medical Institutional Review Board according to internationally accepted criteria for studies on humans, including the Helsinki Declaration. Each patient's family or guardian provided signed consent. Contused brain tissue biopsies were obtained from patients undergoing surgery for brain contusions 6 -98 h after trauma.
During surgery, following evacuation of the contusion-associated necrotic tissue, which could be easily suctioned away, the peri-contusional area was macroscopically identified as the adjacent region of grey matter that could not be easily suctioned. This region of injured tissue provides a safety margin during contusion removal. A biopsy with a volume of approximately 1 cm 3 was obtained from the peri-contusional area, and was snap-frozen in liquid nitrogen and stored at -80°C.
NUCLEAR PROTEIN EXTRACTION AND EMSA
Nuclear protein was extracted and quantified as described previously. 7 Electrophoretic mobility shift assay (EMSA) was performed using a commercial kit (Gel Shift Assay System, Promega, Madison, WI, USA). The PPAR-α consensus oligonucleotide probe (5′-GAGCTTGGACCAGGACAAAGGT CACGTTCGGGA-3′) was end-labelled with [γ-32 P]adenosine triphosphate (Free Biotech, Beijing, China) and T4-polynucleotide kinase. Nuclear protein (40 µg) was preincubated in a total volume of 9 µl of binding buffer, comprising 10 mM Tris-HCl (pH 7.5), 4% glycerol, 1 mM MgCl 2 , 0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM dithiothreitol (DTT), 50 mM NaCl and 0.05 mg/ml poly(dI-dC) for 10 min at room temperature. After addition of the 32 Plabelled oligonucleotide probe, incubation was continued for 20 min at room temperature. The specificity of the DNA/protein was determined by competition reactions in which a 100-fold molar excess of unlabelled PPAR-α oligonucleotide (specific competitor) or unlabelled AP-2 oligonucleotide (non-specific competitor) was added to the binding reaction 10 min before addition of the radiolabelled probe using HeLa nuclear extract. The reaction was stopped by adding 1 µl of gel loading buffer (×6 concentrate) (Promega) and the mixture was subjected to non-denaturing 4% polyacrylamide gel electrophoresis in 0.4 M Tris-borate-EDTA (TBE) buffer, pH 7.5. The gel was vacuum-dried and exposed to X-ray (Fuji Hyperfilm; Fuji, Tokyo, Japan) at -70°C with an intensifying screen.
IMMUNOHISTOCHEMICAL STUDY
Immunohistochemical studies were conducted on formalin-fixed, paraffinembedded sections. Anti-PPAR-α polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1:100 in 0.2 M phosphate-buffered saline (PBS), pH 7.4, was used. For immunohistochemistry, the sections were incubated in PBS with 5% D Feng, Y Zhang, G Chen Cortical expression of PPAR-a after brain contusion normal horse serum and 0.3% Triton X-100 for 1 h at room temperature. They were washed three times with PBS and incubated with primary antibody for 2 h at room temperature. After washing with PBS, the sections were incubated with biotinylated second antibodies for 1 h at room temperature. Sections incubated in the absence of primary antibody were used as negative controls. Microscopy of the immunohistochemically stained tissue sections was performed by an experienced pathologist blinded to the experimental conditions. The number of positively immunostained cells in each section was counted in 10 microscope fields (at ×200 magnification) throughout identical regions of the injured brain and the mean per visual field was calculated. The number of PPAR-α-positively immunostained microvessels in each section was also counted in 10 microscope fields (at ×100 magnification) and the mean per visual field was calculated.
STATISTICAL ANALYSIS
All data are presented as the mean ± SD. Statistical evaluation of the data was carried out using the Statistical Package for Social Sciences (SPSS ® version 12.0; SPSS Inc., Chicago, IL, USA). The data between groups were analysed by one-way analysis of variance followed by Fisher's least significant difference post hoc test. A P-value < 0.05 was considered to be statistically significant.
Results
Eleven contused brain tissue biopsies were obtained from 12 patients undergoing surgery for brain contusions 6 -98 h after trauma ( General data for the 11 patients with brain contusion who underwent surgery 6 -98 h after traumatic brain injury. One patient underwent two operations at 11 and 35 h postinjury (cases 2 and 6, respectively) D Feng, Y Zhang, G Chen Cortical expression of PPAR-a after brain contusion two operations at 11 and 35 h post-injury (cases 2 and 6, respectively). The biopsy tissues were divided into three groups based on the time from patients' trauma to operation: < 24 h (n = 4), 24 -72 h (n = 4), > 72 h (n = 4).
The EMSA autoradiography of PPAR-α DNA binding activity of the 12 injured-brain samples is shown in Fig. 1 . Significantly increased PPAR-α binding activity (strong EMSA autoradiography) was found in the patients who were operated on 24 -72 h A D Feng, Y Zhang, G Chen Cortical expression of PPAR-a after brain contusion after trauma compared with both the < 24 h and the > 72 h groups (P < 0.05). In the patient who underwent two operations, the PPAR-α binding activity was considerably upregulated at 35 h post-injury compared with at 11 h post-injury, as shown in lanes 6 and 2, respectively, of Fig. 1 .
Immunohistochemical study showed that positive PPAR-α was mainly located in the glial cells and vascular endothelial cells, with a little expression in the neurons. Immunoreactivity of PPAR-α was weak in the early stage post-injury (< 24 h) with only a few PPAR-α-positive cells in the injured brain (Fig. 2) . More PPAR-α positively immunostained glial cells and endothelial cells Fig. 3 ). In the > 72 h group, the number of PPAR-α-positive cells was significantly less (P < 0.01) than in the 24 -72 h group, but the immunoreactivity was still strong (Fig. 4) . The PPAR-α immunoreactivity of parenchymal cells and vascular endothelial cells in the injured brain peaked at 24 -72 h after cortical contusion. Compared with both the < 24 h and > 72 h groups, the PPAR-α positively immunostained parenchyma cells and vessels were significantly increased at 24 -72 h (P < 0.01, Fig. 4 ).
Discussion
The present clinical study is the first report that we are aware of to show upregulation of PPAR-α in human contused brain. The PPARα binding activity was time-dependent, showing a remarkable increase after brain injury. A weak expression of PPAR-α was observed in the early stage of trauma, and the maximal expression occurred at 24 -72 h post-injury. Immunohistochemical study showed that PPAR-α was mainly localized at both neuroglial cells and vascular epithelial cells, and with a little at the neurons. These clinical findings suggest that the expression of PPAR-α was upregulated after TBI, which might be a self-protective response mechanism of the central nervous system (CNS) to TBI. 
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Three different isoforms of PPARs are recognized: α, β/δ and γ. The PPARs are implicated in several physiological processes, such as the regulation of lipoprotein, lipid metabolism and glucose homeostasis. 8 In humans, PPAR-α has been cloned and found to be expressed in the muscle, kidney, liver and heart. Compared with animals, the distribution of PPAR-α in humans is somewhat different, with higher levels in human liver and lower levels in human kidney and muscle. 9 We have found no information in the literature, however, regarding PPAR-α expression in the human brain. Moreno et al. 10 showed a complete localization map of PPAR-α expression in the whole CNS of adult rats. They found that PPAR-α was located in both neuronal and glial cells in the frontal and temporal neocortex, which was somewhat in agreement with the present study. Our data demonstrated however that, following TBI, the expression of PPAR-α was changed in the injured human brain. Like the neuroglial cells, the microvasculature also became a main positive location of PPAR-α. Of surprise in the present study, was that we found the expression of PPAR-α in neurons to be not as great as that reported in the literature. 10 In fact, we could only find a few PPAR-αpositive neurons in the early stage following TBI (< 24 h post-injury).
The present study also evaluated PPAR-α activity in the brain of TBI patients and found that the maximum DNA-binding activity of PPAR-α occurred at earlier or later stages than for other transcription factors. For example, we found that maximum PPAR-α activation occurred at 24 -72 h following TBI, whereas it had previously Cortical expression of PPAR-a after brain contusion been reported that maximal binding of cyclic AMP response element binding (CREB), activating protein 1 (AP-1) and NF-κB occurred at 1, 3 and 72 h after TBI, respectively. 11, 12 The time-course of activation of these various transcription factors depends on cellular signalling pathways and on the inducibility of their genes. 13 For example, NF-κB can promote the expression of pro-inflammatory cytokines, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 and acute phase proteins, which are critical to inflammatory processes, 14, 15 whereas AP-1 activation is due to rapid induction of the expression of the immediate early gene c-fos. 16, 17 The signalling mechanism of PPAR-α activation in TBI remains to be elucidated, nevertheless, several mechanisms may be suggested, for example:
(i) direct activation of constitutively expressed PPAR-α by either endogenous ligands or by phosphorylation; 18 and (ii) an indirect mechanism involving a prior induction of PPAR-α expression.
In conclusion, we found an upregulation of PPAR-α binding activity in the human contused brain. PPAR-α activation mainly occurred in the glial cells and vascular endothelial cells, and a little in the neurons. This is the first in vivo demonstration of PPAR-α activation in contused human brain following TBI and may be of use towards understanding the molecular mechanisms responsible for CNS self-protection after acute TBI. Furthering out understanding of the specific role of PPAR-α in brain injury may result in therapies that minimize secondary brain damage and improve the outcome of TBI patients.
